Overview
Zeus is pleased to announce that it has acted as Sole Broker in the oversubscribed £10m placing for Avacta Group plc (AVCT).
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform.
The net proceeds will be used for working capital to progress the Company’s Phase 1a trials of AVA6103 (FAP-Exd) to initial data read out and continue with its existing research and development programs.
Contact
If you would like further information, please get in touch with our team.
This web page constitutes a financial promotion for the purposes of section 21 of the Financial Services and Markets Act 2000 and has been approved by Zeus Capital Limited, which is authorised and regulated by the Financial Conduct Authority.